Evaxion's AML Vaccine Shows Promising Preclinical Results — Evaxion A/S

Event summary

Evaxion presented new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML), at the EHA 2026 Congress on June 13, 2026.
EVX-04 demonstrated complete expression in human cells, enabling immune recognition and activation.
The vaccine induced specific immune responses and targeted cell-killing in both in vivo (mice) and in vitro (human cells) studies.
EVX-04 targets non-conventional endogenous retrovirus (ERV) tumor antigens from the dark genome, identified using Evaxion's AI-Immunology™ platform.

The big picture

Evaxion's EVX-04 represents a novel approach to AML treatment, leveraging AI to identify and target non-conventional tumor antigens. The preclinical data suggests potential for a more effective and less toxic alternative to current low-intensity chemotherapy options, which have a 3-year overall survival rate of only 25% for elderly patients. The success of EVX-04 could pave the way for similar AI-driven immunotherapies across other cancer types.

What we're watching

Regulatory Progress: The pace at which Evaxion advances EVX-04 through regulatory filings for clinical testing.
Clinical Translation: Whether the preclinical success of EVX-04 translates into effective clinical outcomes for AML patients.
Market Differentiation: How EVX-04's off-the-shelf design and AI-driven target selection will position it against existing AML treatments.